Intraday Performance and Price Movement
The stock opened sharply lower with a gap down of -4.85%, setting the tone for a challenging trading session. Throughout the day, Anthem Biosciences Ltd continued to lose ground, ultimately hitting a low of Rs 608.4, marking a decline of -7.96% from the previous close. This intraday low represents a significant underperformance relative to the Pharmaceuticals & Biotechnology sector, where the stock lagged by -4.59% today.
Adding to the pressure, the stock recorded a day change of -5.17%, underperforming the broader market benchmark, the Sensex, which fell by -2.99% during the same period. Anthem Biosciences Ltd’s one-day performance of -5.34% further emphasises the stock’s relative weakness compared to the Sensex’s -2.73% decline.
Technical Indicators and Moving Averages
From a technical standpoint, Anthem Biosciences Ltd is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based weakness across short, medium, and long-term technical indicators signals persistent downward momentum. The stock’s current Mojo Score stands at 50.0 with a Mojo Grade of Hold, an improvement from its previous Sell rating as of 4 March 2026, yet the market response today suggests caution remains warranted.
The stock has been on a downward trajectory for seven consecutive trading days, accumulating a loss of -11.36% over this period. This sustained decline highlights ongoing selling pressure and a lack of immediate buying support.
Patience pays off here! This Micro Cap from Fertilizers sector has delivered steady gains quarter after quarter. Now proudly part of our Reliable Performers list.
- - New Reliable Performer
- - Steady quarterly gains
- - Fertilizers consistency
Market Context and Sector Comparison
The broader market environment has been challenging, with the Sensex opening sharply lower by -1,862.15 points and further declining by -495.70 points to close at 76,561.05, down -2.99%. This marks the Sensex’s third consecutive weekly fall, accumulating a loss of -7.55% over the last three weeks. Several indices, including NIFTY Realty, S&P Bse Dollex 30, and NIFTY IT, hit new 52-week lows today, underscoring widespread market weakness.
Within this context, Anthem Biosciences Ltd’s underperformance is notable. Its one-week return of -8.87% is double the Sensex’s -4.33% decline, and its one-month performance of -7.04% compares unfavourably to the Sensex’s -8.68%, though the stock has marginally outperformed the benchmark over three months (-4.95% vs. -9.33%). Year-to-date, the stock has declined by -3.89%, while the Sensex has fallen by -9.92%, indicating some relative resilience over the longer term despite recent volatility.
Longer-Term Performance and Market Capitalisation
Anthem Biosciences Ltd’s market capitalisation grade is rated 2, reflecting its mid-cap status within the Pharmaceuticals & Biotechnology sector. Over the past year, the stock has remained flat with a 0.00% return, contrasting with the Sensex’s 3.27% gain. Over three and five years, the stock has also shown no price appreciation, while the Sensex has delivered robust returns of 28.36% and 50.44%, respectively. The ten-year performance similarly shows no change for Anthem Biosciences Ltd, compared to the Sensex’s substantial 209.61% gain.
This long-term stagnation, combined with recent price declines, highlights the stock’s current challenges in regaining upward momentum amid a volatile market backdrop.
Why settle for Anthem Biosciences Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology mid-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Sentiment and Immediate Pressures
Investor sentiment towards Anthem Biosciences Ltd remains subdued amid the broader market downturn and sector-specific headwinds. The stock’s continuous seven-day losing streak and its position below all major moving averages indicate persistent selling pressure. The gap down opening today and the subsequent intraday low reinforce the cautious stance among market participants.
While the stock’s Mojo Grade has improved from Sell to Hold as of 4 March 2026, the current price action suggests that this upgrade has yet to translate into positive momentum. The Pharmaceuticals & Biotechnology sector itself is facing pressure, as reflected in the stock’s underperformance relative to its peers and the broader market indices.
Overall, the combination of technical weakness, sectoral challenges, and a broadly negative market environment has contributed to Anthem Biosciences Ltd’s intraday low and ongoing price pressure.
Summary
Anthem Biosciences Ltd’s stock performance today highlights the challenges faced amid a weakening market and sector backdrop. The stock’s intraday low of Rs 608.4, a decline of -7.96%, coupled with its gap down opening and sustained losses over the past week, underscores the immediate pressures weighing on the share price. Trading below all key moving averages and underperforming the Sensex and sector indices, the stock remains in a technically weak position. Broader market declines and sector-specific softness have compounded the stock’s downward momentum, resulting in a cautious trading environment for Anthem Biosciences Ltd.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
